AstraZeneca's COVID prevention drug meets primary goals in late-stage study

AstraZeneca's long-acting antibody therapy, sipavibart, showed a significant reduction in symptomatic COVID-19 cases in immunocompromised patients. The drugmaker withdrew its COVID-19 vaccine due to surplus availability of updated vaccines. Immunocompromised patients, constituting 25% of COVID-19 hospitalizations and deaths, may benefit from this novel prevention therapy, addressing a critical need.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XHbhcNS
via IFTTT